What's new in the biology and treatment of undifferentiated carcinoma of nasopharyngeal type?

[1]  D. Goldenberg,et al.  Epstein-Barr virus and cancers of the head and neck. , 2001, American journal of otolaryngology.

[2]  J. Sham,et al.  Long term results of radioactive gold grain implantation for the treatment of persistent and recurrent nasopharyngeal carcinoma , 2001, Cancer.

[3]  Shinn-Yn Lin,et al.  Presence of Epstein‐Barr virus latent membrane protein 1 gene in the nasopharyngeal swabs from patients with nasopharyngeal carcinoma , 2001, Head & neck.

[4]  G. Reynolds,et al.  Heterogeneity of HLA and EBER expression in epstein‐barr virus‐associated nasopharyngeal carcinoma , 2000, International journal of cancer.

[5]  S. Leung,et al.  Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. , 2000, Cancer research.

[6]  J. Burgos,et al.  Immunohistochemical Absence of CD21 Membrane Receptor in Nasopharyngeal Carcinoma Cells Infected by Epstein‐Barr Virus in Spanish Patients , 2000, The Laryngoscope.

[7]  R. Longnecker,et al.  Epstein-Barr virus entry into cells. , 2000, Virology.

[8]  G. Niedobitek.  Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma , 2000, Molecular pathology : MP.

[9]  L. Young,et al.  The expression and function of Epstein-Barr virus encoded latent genes , 2000, Molecular pathology : MP.

[10]  J. Cohen,et al.  Epstein-Barr virus infection. , 2000, The New England journal of medicine.

[11]  T. Yoshizaki,et al.  Association of latent membrane protein 1 and matrix metalloproteinase 9 with metastasis in nasopharyngeal carcinoma , 2000, Cancer.

[12]  S. Leung,et al.  Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. , 2000, Cancer research.

[13]  J. Armand,et al.  Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  U. Prasad,et al.  Analysis and Significance of Anti-Latent Membrane Protein-1 Antibodies in the Sera of Patients with EBV-Associated Diseases , 2000, The Journal of Immunology.

[15]  W. Wei,et al.  Salvage surgery for recurrent primary nasopharyngeal carcinoma. , 2000, Critical reviews in oncology/hematology.

[16]  R. Longnecker,et al.  Epstein-Barr virus latency: LMP2, a regulator or means for Epstein-Barr virus persistence? , 2000, Advances in cancer research.

[17]  S. Maruo,et al.  Oncogenic Role of Epstein-Barr Virus-Encoded RNAs in Burkitt’s Lymphoma Cell Line Akata , 1999, Journal of Virology.

[18]  S. Leung,et al.  Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. , 1999, Cancer research.

[19]  N. Raab-Traub,et al.  Epithelial Cell Adhesion to Extracellular Matrix Proteins Induces Tyrosine Phosphorylation of the Epstein-Barr Virus Latent Membrane Protein 2: a Role for C-Terminal Src Kinase , 1999, Journal of Virology.

[20]  S. Leung,et al.  Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. , 1999, Cancer research.

[21]  S. Burrows,et al.  X-Linked Agammaglobulinemia Patients Are Not Infected with Epstein-Barr Virus: Implications for the Biology of the Virus , 1999, Journal of Virology.

[22]  I. Ernberg,et al.  Horizontal transfer of DNA by the uptake of apoptotic bodies. , 1999, Blood.

[23]  S. Thongprasert,et al.  Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian-Oceanian Clinical Oncology Associati , 1998 .

[24]  S. Thongprasert,et al.  Preliminary report of the asian‐oceanian clinical oncology association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma , 1998, Cancer.

[25]  J. R. Wong.  Is chemotherapy beneficial in the treatment of locoregionally advanced nasopharyngeal carcinoma? , 1998, Cancer.

[26]  A. Lee,et al.  Nasopharyngeal carcinoma in situ , 1998, Cancer.

[27]  D. Thorley-Lawson,et al.  EBV persistence in memory B cells in vivo. , 1998, Immunity.

[28]  K. Takada,et al.  Cell-to-Cell Contact as an Efficient Mode of Epstein-Barr Virus Infection of Diverse Human Epithelial Cells , 1998, Journal of Virology.

[29]  M. Leblanc,et al.  Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  T. Yoshizaki,et al.  The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[31]  A. Eliopoulos,et al.  Epstein–Barr virus: LMP1 masquerades as an active receptor , 1998, Current Biology.

[32]  L. Young,et al.  Epstein – Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-κB pathway involving TNF receptor-associated factors , 1997, Oncogene.

[33]  H. Herbst,et al.  EPSTEIN–BARR VIRUS (EBV) INFECTION IN INFECTIOUS MONONUCLEOSIS: VIRUS LATENCY, REPLICATION AND PHENOTYPE OF EBV‐INFECTED CELLS , 1997, The Journal of pathology.

[34]  A. Carbone,et al.  Clinicopathological Consultation Lymphoepithelial Carcinoma of the Larynx, Hypopharynx, and Trachea , 1997, The Annals of otology, rhinology, and laryngology.

[35]  W. Chen,et al.  The mechanism of Epstein-Barr virus infection in nasopharyngeal carcinoma cells. , 1997, The American journal of pathology.

[36]  M. Vasef,et al.  Nasopharyngeal Carcinoma, with Emphasis on its Relationship to Epstein-Barr Virus , 1997, The Annals of otology, rhinology, and laryngology.

[37]  K. L. Fries,et al.  Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene , 1996, Journal of virology.

[38]  E. Kieff,et al.  CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1: involvement of TRAF3 as a common mediator. , 1996, Oncogene.

[39]  Jie Yang,et al.  Epstein-Barr virus as a therapeutic target in Hodgkin's disease and nasopharyngeal carcinoma. , 1996, Seminars in cancer biology.

[40]  Vumca I Trial.  Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV(> or = N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. , 1996, International journal of radiation oncology, biology, physics.

[41]  G. Winberg,et al.  Antibodies to LMP2A/2B in EBV-carrying malignancies. , 1995, European journal of cancer.

[42]  L. Young,et al.  Expression of immune regulatory molecules in Epstein-Barr virus-associated nasopharyngeal carcinomas with prominent lymphoid stroma. Evidence for a functional interaction between epithelial tumor cells and infiltrating lymphoid cells. , 1995, The American journal of pathology.

[43]  Kathryn Flynn,et al.  Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. , 1995, The New England journal of medicine.

[44]  W. Miller,et al.  The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor , 1995, Journal of virology.

[45]  P. Yuen,et al.  Maxillary swing approach for resection of tumors in and around the nasopharynx. , 1995, Archives of otolaryngology--head & neck surgery.

[46]  U. Prasad,et al.  Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus-infected neoplasia. , 1995, The American journal of pathology.

[47]  G. Srivastava,et al.  Evidence for lytic infection by Epstein‐Barr virus in mucosal lymphocytes instead of nasopharyngeal epithelial cells in normal individuals. , 1995, Journal of medical virology.

[48]  Y. W. Zhang,et al.  Differences in the growth pattern and clinical course of EBV-LMP1 expressing and non-expressing nasopharyngeal carcinomas. , 1995, European journal of cancer.

[49]  L. Young,et al.  Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state , 1994, Journal of virology.

[50]  J. Armand,et al.  [Undifferentiated carcinoma of the nasopharynx: epidemiological, clinical and therapeutic aspects]. , 1994, Bulletin du cancer.

[51]  J. Armand,et al.  Nasopharyngeal cancer: epidemiology, staging, and treatment. , 1994, Seminars in oncology.

[52]  U. Prasad,et al.  Analysis of epstein‐barr virus infection in nasopharyngeal biopsies from a group at high risk of nasopharyngeal carcinoma , 2009, International journal of cancer.

[53]  D. Martel-Renoir,et al.  Expression of the Epstein-Barr virus immediate early gene, BZLF1, in nasopharyngeal carcinoma tumor cells. , 1993, Virology.

[54]  U. Zimber-Strobl,et al.  Characterization of the antibody response to the latent infection terminal proteins of Epstein-Barr virus in patients with nasopharyngeal carcinoma. , 1993, The Journal of general virology.

[55]  M. Wong,et al.  Pathological basis of surgery in the management of postradiotherapy cervical metastasis in nasopharyngeal carcinoma. , 1992, Archives of otolaryngology--head & neck surgery.

[56]  Q Y Yao,et al.  Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts , 1992, Journal of virology.

[57]  U. Prasad,et al.  Expression of Epstein-Barr virus genes and of lymphocyte activation molecules in undifferentiated nasopharyngeal carcinomas. , 1992, The American journal of pathology.

[58]  L. Young,et al.  Epstein–Barr virus infection and replication in a human epithelial cell system , 1992, Nature.

[59]  Q. Yao,et al.  Immunoglobulin A-induced shift of Epstein-Barr virus tissue tropism. , 1992, Science.

[60]  J. Sham,et al.  Immunoglobulin A against viral capsid antigen of Epstein‐Barr virus and indirect mirror examination of the nasopharynx in the detection of asymptomatic nasopharyngeal carcinoma , 1992, Cancer.

[61]  H. Stein,et al.  The Epstein-Barr virus encoded membrane protein (LMP) induces phenotypic changes in epithelial cells , 1992, Virchows Archiv. B, Cell pathology including molecular pathology.

[62]  A. Levine,et al.  The oncogenic potential of Epstein-Barr virus nuclear antigen 1 in transgenic mice. , 1992, Current topics in microbiology and immunology.

[63]  W. Fee,et al.  Long-term survival after surgical resection for recurrent nasopharyngeal cancer after radiotherapy failure. , 1991, Archives of Otolaryngology - Head and Neck Surgery.

[64]  J. Armand,et al.  Chemotherapy of metastatic and/or recurrent undifferentiated nasopharyngeal carcinoma with cisplatin, bleomycin, and fluorouracil. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  C. V. van Hasselt,et al.  Nasopharyngeal Carcinoma: Modes of Presentation , 1991, The Annals of otology, rhinology, and laryngology.

[66]  J. Epstein,et al.  Abundant expression of EBER1 small nuclear RNA in nasopharyngeal carcinoma. A morphologically distinctive target for detection of Epstein-Barr virus in formalin-fixed paraffin-embedded carcinoma specimens. , 1991, The American journal of pathology.

[67]  J. Cooper,et al.  The relationship of nasopharyngeal carcinomas and second independent malignancies based on the radiation therapy oncology group experience , 1991, Cancer.

[68]  A. Levine,et al.  Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin 6 , 1990, Cell.

[69]  G. Klein,et al.  Morphological transformation of human keratinocytes expressing the LMP gene of Epstein Barr virus , 1990, Nature.

[70]  L. Young,et al.  Epstein–Barr virus latent membrane protein inhibits human epithelial cell differentiation , 1990, Nature.

[71]  J. Armand,et al.  High complete response in advanced nasopharyngeal carcinoma with bleomycin, epirubicin, and cisplatin before radiotherapy. , 1990, Journal of the National Cancer Institute.

[72]  J. Sham,et al.  Detection of subclinical riasopharyngeal carcinoma by fibreoptic endoscopy and multiple biopsy , 1990, The Lancet.

[73]  J. Sham,et al.  Multiple malignant neoplasms in patients with nasopharyngeal carcinoma. , 1990, Oncology.

[74]  D. Choy,et al.  In situ detection of Epstein-Barr virus markers in nasopharyngeal carcinoma patients. , 1989, Oncology.

[75]  I. Ernberg,et al.  Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: implications for sites of viral latency. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[76]  D. Hartmann,et al.  Detection of antigens associated with Epstein-Barr virus replication in extracts from biopsy specimens of nasopharyngeal carcinomas. , 1988, Journal of the National Cancer Institute.

[77]  T. Tursz,et al.  Epstein-Barr virus gene expression in nasopharyngeal carcinoma. , 1988, The Journal of general virology.

[78]  A. Huang,et al.  The differentiated form of nasopharyngeal carcinoma contains epstein‐barr virus DNA , 1987, International journal of cancer.

[79]  N. Raab-Traub,et al.  The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation , 1986, Cell.

[80]  C. Micheau.  What's new in histological classification and recognition of naso-pharyngeal carcinoma (N.P.C.). , 1986, Pathology, research and practice.

[81]  E. Lennette,et al.  Replication of Epstein-Barr virus within the epithelial cells of oral "hairy" leukoplakia, an AIDS-associated lesion. , 1985, The New England journal of medicine.

[82]  E. Kieff,et al.  An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells , 1985, Cell.

[83]  M. Epstein,et al.  A re‐examination of the epstein‐barr virus carrier state in healthy seropositive individuals , 1985, International journal of cancer.

[84]  D. Reisman,et al.  A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[85]  N. Raab-Traub,et al.  Replication of Epstein–Barr virus in human epithelial cells infected in vitro , 1983, Nature.

[86]  A. Carbone,et al.  Pitfalls in microscopic diagnosis of undifferentiate carcinoma of nasopharyngeal type (lymphoepithelioma) , 1982, Cancer.

[87]  M. Epstein,et al.  Isolation of infectious EB virus from the epithelial tumour cells of nasopharyngeal carcinoma , 1977, International journal of cancer.

[88]  W. Henle,et al.  Epstein‐barr virus‐specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma , 1976, International journal of cancer.

[89]  C. Wells.  Ancient Egyptian Pathology , 1963, The Journal of Laryngology & Otology.

[90]  C. Jackson.  PRIMARY CARCINOMA OF THE NASOPHARYNX. A TABLE OF CASES. , 1901 .